G01N33/539

Dual range cardiac troponin immunoassay devices and methods using immunosensor and magnetic immunosensor

The present invention relates to systems and methods that utilize a combination of immunoassay and magnetic immunoassay techniques to detect an analyte within an extended range of specified concentrations. In particular, a device includes a first immunosensor including an immobilized layer of capture antibodies configured to bind to a first complex of signal antibodies and cardiac troponin such that a second complex of the first complex and the immobilized layer of capture antibodies is localized on or near the first immunosensor. The device further includes a second immunosensor having a magnetic field disposed locally around the second immunosensor. The magnetic field is configured to attract magnetic beads such that a third complex of the first complex and capture antibodies immobilized on the magnetic beads is localized on or near the second immunosensor sensor.

Dual range cardiac troponin immunoassay devices and methods using immunosensor and magnetic immunosensor

The present invention relates to systems and methods that utilize a combination of immunoassay and magnetic immunoassay techniques to detect an analyte within an extended range of specified concentrations. In particular, a device includes a first immunosensor including an immobilized layer of capture antibodies configured to bind to a first complex of signal antibodies and cardiac troponin such that a second complex of the first complex and the immobilized layer of capture antibodies is localized on or near the first immunosensor. The device further includes a second immunosensor having a magnetic field disposed locally around the second immunosensor. The magnetic field is configured to attract magnetic beads such that a third complex of the first complex and capture antibodies immobilized on the magnetic beads is localized on or near the second immunosensor sensor.

Assays for detecting the presence or amount of an anti-drug antibody

Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.

Assays for detecting the presence or amount of an anti-drug antibody

Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.

METHOD FOR CAPTURING SPECIFIC CELLS

The present invention provides a method for capturing specific cells (e.g. many types of cancer cells, including cancer cells not expressing EpCAM), and a method for analysis of specific cells involving the method. Included is a method for capturing specific cells present in blood or biological fluid, the method including: agglutinating blood cells in sampled blood or biological fluid; centrifuging the resulting blood or biological fluid; and then capturing specific cells therefrom onto a hydrophilic polymer layer.

ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FORM A SAMPLE USING SAME
20190204307 · 2019-07-04 ·

The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.

ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FORM A SAMPLE USING SAME
20190204307 · 2019-07-04 ·

The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.

NOVEL SPECIFIC MONOCLONAL ANTIBODY TO ACETYLATED MOUSE BUBR1 AND PREPARATION METHOD THEREFOR
20190202910 · 2019-07-04 ·

Provided is a rabbit monoclonal antibody to acetylated mouse BubR1 and a preparation method therefor and, more particularly, provides the use of the monoclonal antibody in a method for measuring the activity of cell division checkpoints on the basis of a degree of acetylation of BubR1, a method for detecting a tumor disease on the basis of aberrant cell division, a method for diagnosing cancer, a method for screening anti-cancer agents, or a method for regulating a cell division cycle.

NOVEL SPECIFIC MONOCLONAL ANTIBODY TO ACETYLATED MOUSE BUBR1 AND PREPARATION METHOD THEREFOR
20190202910 · 2019-07-04 ·

Provided is a rabbit monoclonal antibody to acetylated mouse BubR1 and a preparation method therefor and, more particularly, provides the use of the monoclonal antibody in a method for measuring the activity of cell division checkpoints on the basis of a degree of acetylation of BubR1, a method for detecting a tumor disease on the basis of aberrant cell division, a method for diagnosing cancer, a method for screening anti-cancer agents, or a method for regulating a cell division cycle.

IMMUNO CHROMATOGRAPHY METHOD WITH CENTRIFUGE ISOLATION
20190170735 · 2019-06-06 ·

Disclosed is an immune chromatography method with centrifuge isolation. A microparticle (colloidal gold and fluorescent microsphere) as a carrier carries an analyte and an intermediate thereof, and a chromatography flow of the microparticle is performed on a solid phase membrane to complete a reaction, thereby improving a capacity of the solid phase membrane to capture and bind the analyte and the intermediate thereof. A centrifugation device is provided to drive a liquid phase to flow on the solid phase membrane for chromatography, thereby effectively reducing non-specific binding between specifically captured chemiluminescent substances and the solid phase membrane and background noise interference from the solid phase membrane, and promoting detection sensitivity.